volume 9, issue 9, P5315-5322 2020
DOI: 10.21037/tcr-20-1333
View full text
|
|
Share

Abstract: Background: Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for thirdline treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has been proven effective in advanced GC/EGJC.Numerous studies have shown that immunotherapy has a synergistic effect when combined with targeted drug therapy. Based on these facts and to assess the efficacy and safety of programmed death 1 (PD-1) inhibitor and apatini…

expand abstract